Date: 2015-09-11
Type of information: Construction of new premises
Compound:
Company: Merck KGaA (Germany) Merck Serono (Germany)
Therapeutic area:
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On September 11, 2015, Merck Serono, the biopharmaceutical business of Merck KGaA announced the expansion of its R&D facility in Darmstadt, Germany. MerckKGaA is investing € 65 million in a new laboratory building that will span more than 16,000 square meters and accommodate approximately 200 current employees whose focus will be accelerating innovation in R&D. The new building is to be completed in fall of 2017. It will unite different functions within R&D Discovery Technologies at Merck Serono, including Molecular Pharmacology, Medicinal Chemistry, Computational Chemistry, Molecular Interactions and Biophysics, Protein Engineering and Antibody Technologies, and Protein and Cell Sciences. This research building will be located within the new "Pharma Square" on the Merck campus in Darmstadt. Merck is thus uniting a significant part of its R&D activities in a single area, creating ideal conditions for the advancement of its biopharmaceutical pipeline.
Financial terms:
Latest news:
